ArticleEMBO molecular medicine2021
Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 24 citations in OpenAlex.
- Design and validation of a ribosome display library for synthetic nanobody selection.Advanced biotechnology · 2026Article
- In-Depth Molecular Dynamics Simulations Reveal Ligand-Induced Modulations of the HSPA8-SARS-CoV-2 Spike Protein Interaction.International journal of molecular sciences · 2026Article
- Article
- Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.Journal of virology · 2025Article
- A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.Journal of virology · 2024Article
- Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.Viruses · 2024Review
- A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris.Advanced biotechnology · 2024Article
- Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination.Cell discovery · 2024Article
- Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.Structure (London, England : 1993) · 2024Article
- A human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron.Advanced biotechnology · 2024Article
- Article
- Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2.PLoS pathogens · 2023Article
- Multi-structural molecular docking (MOD) combined with molecular dynamics reveal the structural requirements of designing broad-spectrum inhibitors of SARS-CoV-2 entry to host cells.Scientific reports · 2023Article
- Heat-Denatured Lysozyme is a Novel Potential Non-alcoholic Disinfectant Against Respiratory Virus.Food and environmental virology · 2023Article
- Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.Journal of virology · 2023Article
- Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants.Cell discovery · 2023Article
- A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge.Scientific reports · 2023Article
- A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.PLoS pathogens · 2023Article
- SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope.Nature microbiology · 2022Article
- Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.International journal of biological macromolecules · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 8 institutions in 4 countries.
Tingting LiState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.ORCID 0000-0003-3146-2761
Hongmin CaiState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Yapei ZhaoUniversity of CAS, Beijing, China.ORCID 0000-0001-7738-6181
Yanfang LiState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Yanling LaiState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Hebang YaoState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.ORCID 0000-0002-8588-5877
Liu Daisy LiuState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Zhou SunHangzhou Center for Disease Control and Prevention, Hangzhou, China.
Martje Fentener van VlissingenErasmus Laboratory Animal Science Center, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2213-5910
Thijs KuikenEuropean Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.
Corine H GeurtsvanKesselEuropean Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.
Ning ZhangCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China.
Bingjie ZhouUniversity of CAS, Beijing, China.
Lu LuUniversity of CAS, Beijing, China.
Yuhuan GongUniversity of CAS, Beijing, China.
Wenming QinNational Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China.
Moumita MondalCAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China.
Bowen DuanUniversity of CAS, Beijing, China.
Shiqi XuUniversity of CAS, Beijing, China.ORCID 0000-0003-0345-2814
Audrey S RichardEuropean Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.
Hervé RaoulEuropean Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.
JianFeng ChenState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Chenqi XuState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Ligang WuState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Haisheng ZhouState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Zhong HuangCAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China.ORCID 0000-0002-2161-1359
Xuechao ZhangHangzhou Center for Disease Control and Prevention, Hangzhou, China.
Jun LiHangzhou Center for Disease Control and Prevention, Hangzhou, China.
Yanyan WangState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Yuhai BiUniversity of CAS, Beijing, China.
Barry RockxEuropean Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.
Junfang ChenHangzhou Center for Disease Control and Prevention, Hangzhou, China.ORCID 0000-0003-0945-962X
Fei-Long MengState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.ORCID 0000-0003-0333-6872
Dimitri LavilletteCAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China.ORCID 0000-0002-4706-1519
Dianfan LiState Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.ORCID 0000-0003-4729-4678
Chinese Academy of Sciences · CNInstitut Pasteur of Shanghai · CNErasmus MC · NLHangzhou Center for Disease Control and Prevention · CNInstitute of Microbiology · CNEuropean Research Infrastructure on Highly Pathogenic Agents · FRShanghai Advanced Research Institute · CNSoochow University · CN
Funding
CAS Facility-based Open Research ProgramCAS Grant JCTD-2020-17CAS President's International Fellowship Initiative 2020VBA0023European Union's Horizon 2020 Research & Innovation program 824061Innovation Capacity Building Project of Jiangsu province Nanjing Unicorn Academy of innovation BM2020019Key Program of CAS Frontier Science QYZDB-SSW-SMC037Ministry of Science and Technology of China 2017YFA0506700Ministry of Science and Technology of China 2020YFC0845900National Natural Science Foundation of China (NSFC) 31870153National Natural Science Foundation of China (NSFC) 31870726National Natural Science Foundation of China (NSFC) 31970880NSFC Outstanding Young Scholars 31822055RECOVER European Union's Horizon 2020 research and innovation program 101003589Science and Technology Commission of Hangzhou Municipality 202013A02Science and Technology Commission of Shanghai Municipality (STCSM) 20490760200Science and Technology Commission of Shanghai Municipality (STCSM) 20ZR1466700Shanghai Municipal Science and Technology Major Project 20431900402Strategic Priority Research Program of CAS XDB29010102Strategic Priority Research Program of CAS XDB37020204The Key R&D Program of Jiangsu Province (Social Development) Project BE2019625Youth Innovation Promotion Association of the Chinese Academy of Sciences (Youth Innovation Promotion Association CAS) 2017122
Abstract
An essential step for SARS-CoV-2 infection is the attachment to the host cell receptor by its Spike receptor-binding domain (RBD). Most of the existing RBD-targeting neutralizing antibodies block the receptor-binding motif (RBM), a mutable region with the potential to generate neutralization escape mutants. Here, we isolated and structurally characterized a non-RBM-targeting monoclonal antibody (FD20) from convalescent patients. FD20 engages the RBD at an epitope distal to the RBM with a K
Indexed as
COVID-19SARS-CoV-2Antibodies, ViralHumansSpike Glycoprotein, CoronavirusAntibodies, ViralSpike Glycoprotein, CoronavirusCOVID-19cross-active neutralizing antibodydestruction of spikereceptor-binding domainvariants of concern
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.